Respiro Diagnostics secures £1M to advance lung diagnostics

2026-07-08 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Medical Devices & Health Technology, Clinical Care & Medical Practice, Pharmaceuticals & Biotechnology · Depth: Fundamental Awareness, quick

Summary

Respiro Diagnostics, a UK-based startup, has secured £1 million in pre-seed funding led by Zinc Venture Capital and SFC Capital, with participation from Amadeus Capital Partners, the Conception X Angel Syndicate, KQ Labs through the Francis Crick Institute, strategic angel investors, and Innovate UK. The company is developing a non-invasive, breath-based diagnostic platform that analyzes DNA, RNA, and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases. This technology offers an alternative to invasive tissue and blood biopsies, aiming for earlier diagnosis and improved treatment guidance. Respiro has completed initial proof-of-concept testing in mesothelioma patients and plans its first lung cancer clinical study at Aalborg University Hospital in Denmark in September 2026, also evaluating applications in pulmonary hypertension and asthma. The funding will advance clinical research and platform development.

Key takeaway

For investors evaluating early-stage health tech, Respiro Diagnostics' £1 million pre-seed funding underscores growing confidence in non-invasive, breath-based diagnostic platforms. You should consider how such technologies, by offering alternatives to invasive biopsies and enabling earlier detection, could significantly impact patient outcomes and market dynamics in lung disease diagnostics. This investment signals a potential shift in diagnostic methodologies.

Key insights

Respiro Diagnostics develops a non-invasive, breath-based platform for early detection and molecular profiling of lung diseases.

Principles

• Non-invasive diagnostics offer alternatives to traditional biopsies.
• Exhaled breath analysis can yield DNA, RNA, and protein biomarkers.

Method

The platform combines a proprietary breath collection device with laboratory methods to analyze DNA, RNA, and proteins captured from exhaled breath samples.

In practice

• Detect lung cancer and respiratory diseases.
• Guide treatment decisions for lung conditions.

Topics

• Lung Diagnostics
• Breath Biopsy
• Non-invasive Diagnostics
• Pre-seed Funding
• Respiratory Diseases
• Cancer Detection

Best for: Investor, Entrepreneur, Tech Journalist

Related on AIssential

• Spotlight Pathology has raised £1.4M to catch blood cancer sooner — AI-powered image analysis can significantly improve the speed and consistency of blood cancer diagnosis.
• Deep learning-based detection of cessation of breathing in pre-term infants — Deep learning reliably detects infant apnoea using routine NICU signals, with signal modality being key.
• Stripe, Anthropic, and OpenAI are backing an effort to stop respiratory infections — Private philanthropy can drive solutions for technically possible problems lacking commercial incentives, like preventing respiratory viruses.
• iFAST Diagnostics bags £5M to speed up infection testing and tackle antimicrobial resistance — iFAST Diagnostics' rapid AST platform significantly cuts infection testing time from over 40 hours to under three, combating antimicrobial resistance.
• Cricketer Pat Cummins backs longevity startup Everlab’s $65 million Series A - Startup Daily — AI-enhanced preventative healthcare leverages biomarker diagnostics to detect early health issues and coordinate personalized care.
• Preliminary Thoughts On The Midjourney Scanner — Midjourney's new ultrasound tomography scanner faces significant medical limitations and regulatory hurdles for broad diagnostic use.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.